Biotalys Reports Half-Year 2024 Financial Results
Biotalys, a prominent player in Agricultural Technology (AgTech), is making strides in its mission to create protein-based biocontrols for sustainable crop protection. The company has released its consolidated financial results for the first half of 2024, showcasing key accomplishments and outlining future plans.
Business Highlights
In the first half of 2024, Biotalys achieved several significant milestones, including:
- Noteworthy advancements in the regulatory review process for its flagship biofungicide candidate, EVOCA™.
- Successful approval from the Dutch Authority CTGB for large-scale demonstration trials of EVOCA, which also permits the sale of harvested crops.
- The launch of field trials for the next generation of biofungicides, broadening their product offerings.
- The start of an innovative AI project in collaboration with Google DeepMind and Devoteam, utilizing AlphaFold2 technology.
- As of June 30, 2024, the company reported cash and cash equivalents totaling €14.7 million.
- An upcoming conference call and live webcast to discuss financial results and business performance.
CEO Statement
Kevin Helash, the CEO of Biotalys, expressed his enthusiasm about the significant milestones achieved in 2024, particularly through collaborations and product trials. He remarked, "The first half of 2024 has been pivotal for Biotalys, highlighted by our partnership with Novonesis and the launch of new field trials for BioFun-6. We are dedicated to minimizing operational costs and focusing our resources on targeted research efforts."
Regulatory Updates for EVOCA
In the United States, Biotalys is actively collaborating with the Environmental Protection Agency (EPA) on the regulatory review of EVOCA. Preparations are also underway for a next-generation product dossier, EVOCA NG, which is expected to feature reduced production costs.
In Europe, the CTGB is currently reviewing EVOCA and has requested additional information, which Biotalys plans to submit soon. The recent approval for large-scale demonstration trials further emphasizes their confidence in the product's safety, allowing applications across various crops.
Financial Performance Analysis
In the first half of 2024, Biotalys reported other operating income of €1.5 million, primarily driven by R&D tax incentives. Research and development expenses significantly decreased to €5.1 million from €8.6 million during the same period in 2023, reflecting a strategic reduction in external R&D costs.
General and administrative expenses remained steady at €2.8 million. Importantly, net cash used in operating activities dropped to €6.5 million, indicating enhanced financial efficiency due to ongoing cost control measures.
Future Outlook and Strategic Plans
Looking ahead, Biotalys is focused on securing regulatory approval for EVOCA and advancing the development of EVOCA NG in partnership with Novonesis. The company expects to receive results from initial field trials by the end of 2024 and plans to launch a new R&D program targeting an emerging pathogen in the coming months.
With a cash balance of €14.7 million, Biotalys is well-positioned to maintain its financial runway into the second quarter of 2025, providing ample time for growth initiatives and potential financing opportunities.
About Biotalys
Founded in 2013, Biotalys is dedicated to driving innovation in sustainable agriculture through its novel biocontrol solutions, exemplified by their proprietary AGROBODY™ technology platform. The company aims to offer effective alternatives to conventional chemical pesticides, contributing to a safer food supply. Biotalys is publicly traded on Euronext Brussels and is headquartered in Ghent, Belgium.
Frequently Asked Questions
What are the major achievements Biotalys made in the first half of 2024?
Biotalys highlighted significant regulatory progress for EVOCA™, the launch of AI projects, field trials for new biofungicides, and a stable cash position of €14.7 million.
What does the future hold for EVOCA and BIOFUN?
Biotalys plans to continue advancing EVOCA’s regulatory approval and the development of BIOFUN-6, expecting results from early trials by the end of the year.
How did Biotalys perform financially in this reporting period?
Biotalys reported a decrease in operating losses and a reduction in overall expenses, with notable improvements in cash flow management reflected in reduced cash burn.
What is Biotalys' approach to reducing operational costs?
Biotalys has implemented strategic measures to minimize operating cash burn, including reducing external R&D expenses and optimizing operational processes.
How has Biotalys been recognized in the AgTech industry?
Biotalys has received accolades such as the 2024 AgTech Breakthrough Award for Sustainable Crop Protection Company of the Year and has been named among the top 100 in the FoodTech 500 list.
